Taletrectinib, a next-generation TKI, is approved for ROS1-positive NSCLC, showing high ORR and durable responses in clinical trials. TRUST-I and TRUST-II trials demonstrated efficacy in both ...

A new study shows that three common laboratory tests used to determine ROS1 status may return false-negative results, meaning that some patients who could benefit from ROS1-directed therapy may be ...

Zidesamtinib achieved a 44% ORR and 1% CR rate in advanced ROS1-positive NSCLC patients previously treated with ROS1 TKIs. The ARROS-1 trial showed zidesamtinib's efficacy, especially in patients with ...

Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study Responses were durable with ...

An expert explained what ROS1-positive non-small cell lung cancer is and why it is important to identify mutations like ROS1 through genetic sequencing. ROS1-positive non-small cell lung cancer, a ...

Single agent activity of U3-1402, a HER3-targeting antibody-drug conjugate, in breast cancer patients: Phase 1 dose escalation study. This is an ASCO Meeting Abstract from the 2018 ASCO Annual Meeting ...

Drugs like crizotinib are used to treat patients with ROS1-positive lung cancer. But which patients are ROS1-positive? A University of Colorado Cancer Center study published in the Journal of Thoracic ...

Zidesamtinib, an investigational next-generation ROS1 tyrosine kinase inhibitor (TKI) designed to be highly selective, brain-penetrant, and TRK-sparing, demonstrated clinically meaningful activity and ...

A total of 277 patients from 18 countries worldwide responded and completed at least 90% of the survey. The majority of respondents were female (n = 191; 69%), non-Hispanic white (n = 202; 73%), never ...

(RTTNews) - Nuvalent Inc. (NUVL) announced that its New Drug Application seeking approval of Zidesamtinib for treating adult patients with advanced ROS1-positive non-small cell lung cancer has been ...